TRDA · Entrada Therapeutics, Inc.
$5.84
-0.21 (-3.47%)
At close · Jul 24
Market Cap
$227.10M
Shares
38.82M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.05
Open$6.05
Day$5.90–6.35
52W$4.93–16.45
Avg vol 30d375K
Short int2.2M · 5.7% float · 6.3d
Short vol47%
Last earningsMay 7, 2026
DataOct 2021–Jul 2026
Filing10-Q · May 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.6 · elevated
Equity put/call 0.79
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−37%
below
Price vs 50-day avg
−11%
below
RSI (14)
36
neutral
MACD trend
Negative
52-week position
10%
near low
Momentum
relative strength
1-month return
−20%
trailing
6-month return
−48%
trailing
YTD return
−41%
this year
Relative strength
−54%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $10 — 200d above 50d
Institutional flow
Accumulating
16 of 118 funds reported for Jun 30 · net +69.1K sh shares · +4 new
Insider flow
Distributing
Net -$599.4K over 90 days · 67% sells
Short interest
Rising
5.75% of float · ▲ +5.6% MoM · 6.3 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
118 holders — near 3-yr high, broad support
Squeeze score
61
elevated · 0–100
Fundamentals
Revenue growth
−88%
Y/Y
EPS growth
−307%
Y/Y
Free cash flow
$-129.6M
Balance sheet
$90.4M
net cash
Quant / Vol
risk profile
Volatility
86%
annualized · 1-yr
Max drawdown
−65%
past year
ATR
8.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−37%
Bearish
Price vs 50-day avg
−11%
Bearish
RSI (14)
36
Neutral
MACD trend
Negative
Bearish
52-week position
10%
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $7 › 200d $10 — 200d above 50d
Institutional flow
Accumulating
16 of 118 funds reported for Jun 30 · net +69.1K sh shares · +4 new
Insider flow
Distributing
Net -$599.4K over 90 days · 67% sells
Short interest
Rising
5.75% of float · ▲ +5.6% MoM · 6.3 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
118 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $5
Now $6 · 10%
52-wk high $16
vs 200-day avg -37%
vs 50-day avg -11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TRDA
this stock
Entrada Therapeutics, Inc.
|
$227.10M | -41.1% | -87.9% | — | 5.7% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.6% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.16B | +4.4% | +46.2% | 28.3 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.78B | -15.4% | +20.8% | 16.0 | 3.3% |
|
ARGX
Argenx SE
|
$57.44B | +9.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TRDA | -11.9% | -19.8% | -48.1% | -17.8% | -41.2% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | -10.3% | -20.4% | -54.5% | -16.7% | -49.4% |
Key facts
CIK
1689375
CUSIP
29384C108
13F (30d)
16 filings
16 filers
Visit website
Investor relations